Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alzamend Neuro Inc
(NQ:
ALZN
)
1.250
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alzamend Neuro Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
December 02, 2022
We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Friday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 29, 2022
Via
Benzinga
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
November 22, 2022
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 16, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 02, 2022
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday!
Via
InvestorPlace
Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial
October 05, 2022
Via
Benzinga
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
November 15, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
5.6 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying
November 02, 2022
The Nasdaq Composite closed lower by around 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or...
Via
Benzinga
Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study
September 29, 2022
Via
Benzinga
Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate
July 18, 2022
Via
Benzinga
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
October 31, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
WaveDancer And 1 Other Stock Under $2 Insiders Are Aggressively Buying
October 10, 2022
The Dow Jones dropped by more than 600 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
October 05, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 05, 2022
It's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning!
Via
InvestorPlace
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
September 29, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
September 22, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
August 09, 2022
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028.
Via
Benzinga
Alzamend Neuro Stock Pops After Benzinga Exclusive On Cognition Therapeutics Alzheimer's Data
August 04, 2022
Shares of biopharmaceutical company Alzamend Neuro Inc (NASDAQ: ALZN) are soaring Thursday afternoon after Cognition Therapeutics Inc (NASDAQ: CGTX) shares surged following the presentation of a...
Via
Benzinga
6 Penny Stocks With 1,000% Upside Potential
July 24, 2022
Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance.
Via
InvestorPlace
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
July 18, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 22, 2022
Via
Benzinga
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
June 03, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
4 Stocks Under $1 Insiders Are Aggressively Buying
May 27, 2022
The Nasdaq Composite jumped over 300 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
May 17, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Executives Buy Around $5M Of 4 Penny Stocks
May 09, 2022
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the...
Via
Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
April 26, 2022
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...
Via
Benzinga
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
May 05, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
April 28, 2022
From
Alzamend Neuro, Inc.
Via
Business Wire
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
April 28, 2022
From
BitNile Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.